Beam Therapeutics Inc. (BEAM) Stock Forecast
BEAM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 15 analysts
- Price target
- $52.15 average of analyst targets
- Upside to target
- +122.2% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-1.16
- 52-week range
- $20.60 – $37.92
BEAM analyst ratings
15 analystsNumber of analysts at each rating.
BEAM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BEAM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.17 | −$1.28 | −$1.05 | −$1.10 | −6.3% | 13 |
| Current fiscal year (2026) | −$4.45 | −$4.76 | −$4.24 | −$0.81 | −449.8% | 14 |
| Next fiscal year (2027) | −$4.74 | −$5.72 | −$3.56 | −$4.45 | −6.5% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BEAM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $10.0M | $494,900 | $31.7M | +2.7% | 12 |
| Current fiscal year (2026) | $48.6M | $0 | $95.7M | −65.2% | 14 |
| Next fiscal year (2027) | $62.7M | $4.0M | $138.3M | +29.2% | 12 |
BEAM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BEAM revenue: reported and forecast
BEAM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.17 | −$1.17 | −$1.17 | −$1.17 | −$1.17 | −0.4% | 4 up · 5 down |
| Current fiscal year (2026) | −$4.43 | −$4.45 | −$4.45 | −$4.45 | −$4.45 | +0.4% | 4 up · 5 down |
| Next fiscal year (2027) | −$4.73 | −$4.74 | −$4.74 | −$4.74 | −$4.74 | +0.2% | 5 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BEAM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BEAM beat in 9 of 12.
What analysts expect from BEAM
15 analysts cover Beam Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $52.15, 122.2% above the latest close of $23.47. Analysts expect earnings of −$4.45 per share for 2026, −449.8% from a year earlier. For 2027 the average estimate is −$4.74 per share on revenue of $62.7 million. Beam Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: BEAM income statement, BEAM key metrics, BEAM chart. See the BEAM stock overview for the latest quote and news.
BEAM forecast FAQ
What is Beam Therapeutics's price target?
The average analyst price target for Beam Therapeutics is $52.15, 122.2% above the latest close of $23.47.
Is Beam Therapeutics a buy, hold or sell?
Of 15 analysts covering Beam Therapeutics, 12 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Beam Therapeutics's EPS forecast?
Analysts forecast −$4.45 per share for 2026 (range −$4.76 to −$4.24); for 2027 the estimate is −$4.74.
What is Beam Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $48.6 million, growth of −65.2%; for 2027 it is $62.7 million.
When does Beam Therapeutics report earnings?
Beam Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $-1.16.
Does Beam Therapeutics usually beat earnings estimates?
Beam Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.